Synonyms: Inzomelid | MCC-7840 | MCC7840
Compound class:
Synthetic organic
Comment: Emlenoflast (MCC7840 [2]; formerly IZD 174) is one of a growing number of NLRP3 inflammasome inhibitors that have been developed for anti-inflammatory potential [3]. It was developed by Inflazome (acquired by Roche in 2020) as an orally bioavailable drug that is able to cross the blood-brain barrier.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Emlenoflast (MCC7840) inhibits activation of NLRP3-containing inflammasomes, but its precise binding mechanism has not been reported. |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|